Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany

Abstract Background Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in randomized clinical trials. Large-scale, real-world evidence in multi-...

Full description

Saved in:
Bibliographic Details
Main Authors: Andreas Straube, Philipp Stude, Charly Gaul, Katrin Schuh, Mirja Koch
Format: article
Language:EN
Published: BMC 2021
Subjects:
R
Online Access:https://doaj.org/article/4f7b5707f3f94856a2b455887d75c33c
Tags: Add Tag
No Tags, Be the first to tag this record!